Stem Cell TV | Video / Media News

Page 2,857«..10 20..2,8562,8572,858 2,859..2,870 2,880..»

privacy controlled social networking to connect patients with caregivers

Posted: February 19, 2012 at 4:57 pm

Via Scoop.it – inPharmatics
Privacy controlled & safe social network for Healthcare launched by Jonathan Schwartz, Ex-CEO Sun Microsystems. The networks available at http://www.carezone.com Connects Caregivers With family members and allows health-care workers share information about aging or ill parents, spouses and children
Via http://www.bloomberg.com

Source:
http://microarray.wordpress.com/feed/

Posted in Genetic medicine | Comments Off

SOCIAL CRM and its Impact on Pharmaceutical Industry

Posted: February 19, 2012 at 4:57 pm

Source:
http://microarray.wordpress.com/feed/

Posted in Genetic medicine | Comments Off

ACT's Top Scientist Sells $1.5 Million in Company Stock

Posted: February 19, 2012 at 4:57 pm

The mainstream media waxed enthusiastic last month when a California hESC clinical trial reported positive results dealing with blindness.

The report was first published account of a human trial of embryonic stem cell based therapy and involved Advanced Cell Technology, which is headquartered in Santa Monica, Ca. Despite a glowing reception of the trial's results, the firm is years away from being able to market the therapy at a profit – if it ever can do so.

The firm's chief scientific officer, Robert Lanza, moved quickly, however, to capture some monetary gain from the news, which was announced in a press release Jan. 23 by ACT.

On Jan. 23 and 24, Lanza sold 7.7 million shares in ACT for $1.5 million, according to SEC documents. He sold the stock at 18 and 19 cents a share. That compares to an ACT price of about 8 cents at the end of 2011. Lanza still holds 26 million shares in the firm. The acquisition price of the stocks is unknown.

There is nothing to suggest anything untoward about Lanza's sale. But it is a reminder that creating a successful stem cell therapy is about making money. Without a profit, there will be no therapy, as Geron reminded everyone last November when it dropped its longstanding hESC trial.

The California Stem Cell Report has asked Lanza if he has any comments about the sale of the stock. We will carry his remarks verbatim when we receive them.

The Seeking Alpha web site appears to have been the first to report the sale. Here is their complete item.

"Advanced Cell Technology, Inc. (ACTC.OB): ACTC is a development-stage biotech focused on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. On Wednesday, Chief Science Officer Robert Lanza filed SEC Form 4 indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale. ACTC shares have rallied strongly since the beginning of the year, up from 8.2 cents at the end of last year to currently in 14-15c range after rising above 20c just earlier this week."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off

CIRM Contracting: $1.3 Million for IT, $887,282 for Legal

Posted: February 19, 2012 at 4:57 pm

The California stem cell agency this week performed its semi-annual public disclosure of its contracts with outside firms, the second largest item in its operational budget of $18.5 million.

The contracts are scheduled to run about $3.3 million this fiscal year, according to the budget approved last May. That figure is up about 18 percent from the previous year.

According to the contract information posted this week, the two largest contracting expenditures this year are for information technology work, including the ongoing struggles with the grants management system – $1.3 million – and legal help – $887,282. The figures were compiled by the California Stem Cell Report. CIRM did not provide totals.

Outside contracts are second to the cost of salaries and benefits at the agency. One reason for the size of the contracting expense is the small size of the CIRM staff, which is now about 50.

The contracting information will be presented to the CIRM directors' Governance Subcommittee next Friday. The committee is being asked to approve an increase in the contract with Kutir Corp., from $250,000 to $470,000. By the end of 2011, CIRM had already paid out $219,680 to Kutir. The firm provides software development services.

Infonetica, which provides technology advice, would also see an increase from $236,060 to $300,000, under the staff proposal.

A staff memo to the board said,

"(Kutir's) services are key as CIRM continues to progress in automating its grants management systems to meet the requirements of both new RFAs as well as ongoing reporting obligations.""

The public can participate in the Governance meeting at locations in San Francisco, Sacramento, Irvine, Los Angeles, South San Francisco and La Jolla. Specific addresses can be found on the agenda.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Stem Cell Agency on Bee Article and Voter Expectations

Posted: February 19, 2012 at 4:57 pm

The California stem cell agency today said the seven-year-old "audacious vision" of voters when they created the $3 billion research effort "is still possible."

The comment was made in an item on the agency's blog by Amy Adams, the agency's communications manager.

Her entry point was an opinion piece in The Sacramento Bee on Sunday exploring some of the ins and outs of the agency. Among other things, CIRM President Alan Trounson was quoted by writer David Lesher as "optimistically" predicting successful California stem cell treatments in five years.

Adams wrote,

"Lesher makes clear that there are many challenges ahead in bringing new therapies to patients: he said of the voters who created CIRM, 'It was pretty audacious of them in 2004 to try to create another economic driver like Silicon Valley and save lives at the same time.'
"And while the vote was audacious, we agree with his conclusion that despite risks and challenges that vision is still possible."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Blue-Ribbon Panel Seeks Public Comment on California Stem Cell Agency

Posted: February 19, 2012 at 4:57 pm

The California public is being given a chance to weigh in with anonymous comments about what they think of the performance of the $3 billion California stem cell agency.

Their opinions are being sought by a blue-ribbon, Institute of Medicine panel. The IOM is being paid $700,000 by the agency to examine its operations.

The questions include the importance of stem cell research and CIRM's role, its openness and transparency, an assessment of its grant programs and how it should share information with the public, suggestions for improvements and more.

The online form was posted recently on the IOM web site and can be found here. The deadline for submissions is March 19.

The IOM also has survey forms for academic and non-profit CIRM grant recipients, CIRM grant recipients that are businesses(which the IOM calls "industry partners") and "leadership of CIRM-funded institutions." The deadline for those is March 19 as well.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Edmond Veterinary Hospital Offers Pet Stem Cell Therapy for Arthritis

Posted: February 19, 2012 at 4:00 pm

EDMOND, OK--(Marketwire -02/19/12)- The team of veterinarians at White Oaks Veterinary Clinic in Edmond announced that the animal hospital is now offering pet stem cell therapy. This new regenerative medicine for pets helps animals suffering from degenerative joint disease or arthritis. Based on the research and technology provided by a company called Stemlogix, White Oaks Veterinary Clinic can now offer affordable, same-day stem cell therapy to dogs suffering from these debilitating conditions. The Stemlogix technology enables the Edmond veterinarians to extract adult stem cells from a pet's own body fat, virtually eliminating the risk of rejection or negative reaction.

"I see far too many otherwise healthy pets at our veterinary clinic that have been hobbled by the effects of arthritis," Dr. Jennifer Bianchi said. "We're thrilled to be able to offer this holistic solution which harnesses the pet's own healing power to aid in the pain relief process. Our main goal with stem cell therapy is to reduce long-term inflammation and slow the progression of cartilage damage. The motto at our veterinary hospital is, 'Quality service at a great value.' Being able to provide stem cell transplants in about two hours at an affordable rate helps us live up to that promise and makes me happy to think of the pets we'll be able to help move freely again."

The veterinary hospital now has an on-site stem cell laboratory for producing stem cells. The on-site lab allows for immediate processing after extraction as the stem cells have a limited lifespan outside of the pet's body. Once the fat cells have been procured from the pet, the stem cells are isolated and returned back to the host body within ninety minutes. Stemlogix promotes this therapy as being able to relieve pain and increase range of motion in pets suffering with joint pain, arthritis, tendon and ligament damage, hip dysplasia and cartilage damage.

Once implanted, stem cells have the ability to stimulate regeneration, reduce pain and inflammation, and assist in the repair of damaged tissue. They can also differentiate into other cell types such as tendon, cartilage, bone, and ligament, which may further aid the repair process. The Edmond veterinarian says that pain relief can be expected within a few days to a few weeks. Pet owners are cautioned to gradually allow their pets to experience increased activity so as not to interfere with the healing process.

As a holistic veterinarian, White Oaks Veterinary Clinic combines natural healing techniques, such as pet acupuncture, with traditional veterinary medical services. The animal hospital was founded in 1997 and is currently practicing out of a 6500 square foot facility. Equine vet, Dr. Mark Bianchi, offers general and advanced services such as surgery, equine dentistry, lameness evaluations and reproduction consultations.

White Oaks Veterinary Clinic is located at 131 W. Waterloo Rd. Further information on the animal hospital or pet stem cell therapy may be obtained by visiting the website at http://www.whiteoaksvet.com.

Read the original:
Edmond Veterinary Hospital Offers Pet Stem Cell Therapy for Arthritis

Posted in Cell Medicine | Comments Off

Stem cells used to increase bone strength

Posted: February 19, 2012 at 9:20 am

A research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the bloodstream, directs the body's stem cells to travel to the surface of bones.

Once these cells are guided to the bone surface by this molecule, the stem cells differentiate into bone-forming cells and synthesize proteins to enhance bone growth. The study, which was published online today in Nature Medicine, used a mouse model of osteoporosis to demonstrate a unique treatment approach that increases bone density and prevents bone loss associated with aging and estrogen deficiency.

"There are many stem cells, even in elderly people, but they do not readily migrate to bone," said Wei Yao, the principal investigator and lead author of the study. "Finding a molecule that attaches to stem cells and guides them to the targets we need is a real breakthrough."

Researchers are exploring stem cells as possible treatments for a wide variety of conditions and injuries, ranging from peripheral artery disease and macular degeneration to blood disorders, skin wounds and diseased organs. Directing stem cells to travel and adhere to the surface of bone for bone formation has been among the elusive goals in regenerative medicine.

The researchers made use of a unique hybrid molecule, LLP2A-alendronate, developed by a research team led by Kit Lam, professor and chair of the UC Davis Department of

Biochemistry and Molecular Medicine. The researchers' hybrid molecule consists of two parts: the LLP2A part that attaches to mesenchymal stem cells in the bone marrow, and a second part that consists of the bone-homing drug alendronate. After the hybrid molecule was injected into the bloodstream, it picked up mesenchymal stem cells in the bone marrow and directed those cells to the surfaces of bone, where the stem cells carried out their natural bone-formation and repair functions.

"Our study confirms that stem-cell-binding molecules can be exploited to direct stem cells to therapeutic sites inside an animal," said Lam, who also is an author of the article. "It represents a very important step in making this type of stem cell therapy a reality."

See the article here:
Stem cells used to increase bone strength

Posted in Stem Cells | Comments Off

Stem-cell scientists find right chemistry

Posted: February 19, 2012 at 9:20 am

The day – Valentine’s Day, as it happened – began in a whirl of coffee cups, bustling dogs and homework, then a brisk walk around the block – in other words, business as usual for a UC Irvine couple who are a high-profile science team engaged in cutting-edge stem-cell research.

Brian Cummings and Aileen Anderson, whose stem-cell treatment for spinal cord injury is being tested on patients in Switzerland, say their office – only a short walk from their home on the UCI campus – has a family feel as well.

At UCI’s recently constructed Stem Cell Research Center, they supervise a crew of young students and technicians whose bond with their mentors is so close that they call themselves the “Andermings.”

“I suppose it’s like having an orphanage,” Cummings joked as he prepared for the day ahead.

It would include a lengthy meeting with the Andermings on how best to grow human embryonic stem cells without animal-cell contamination, a critique of a doctoral candidate’s presentation of potentially significant new findings and a session with Alzheimer’s researchers at an institute called UCI MIND.

But first, Cummings, Anderson and their two dogs – Chesapeake and Indiana – had to get the couple’s 6-year-old daughter, Camryn, to school.

After Camryn finished her homework (completed strategically a day in advance, leaving more time for afternoon play), they took the long way round to the Montessori school, also easy walking distance from their home.

Along the way, they encountered another faculty couple, from the German department, and their dog. They stopped with Camryn, giggling as the dogs rolled and tumbled on a neighbor’s lawn.

•••

Cummings, 47, and Anderson, 45, together since they were both undergrads at the University of Illinois, say living and working with each other comes naturally.

“People say, ‘Do I need a break from her?’ ” Cummings said as he wrangled the dogs.

“More people say, ‘Do you need a break from him?’ ” Anderson replied.

Later, the conversation transitions into a science meeting as the two take the 20-minute walk past UCI’s Ecological Preserve and into the Sue and Bill Gross Stem Cell Research Center. The energy-efficient building, with an open design to encourage chance meetings among scientists, houses a roster of high-powered researchers as well as their experimental subjects: rodents.

The center was seeded by $27 million in state stem-cell funding and $10 million from donors Bill and Sue Gross. The building was completed in 2010.

Now, researchers working there cultivate lines of human embryonic stem cells that can grow into a variety of cell types, from brain cells to liver and heart cells.

The ability to coax stem cells into many forms – and with it the potential to treat Alzheimer’s, paralysis and a long list of diseases – is fueling an explosion of research around the nation and across the state.

Anderson and Cummings showed that their stem-cell treatment, using cells derived from aborted fetuses, allowed partially paralyzed rats to walk again. The rat’s recovery was revealed in a dramatic before-and-after video.

So far, the human trial of the treatment in Switzerland is showing no ill effects on patients, Cummings said.

But stem-cell research is buffeted by political controversy, funding uncertainties and, sometimes, attacks by stem-cell research opponents.

The trial of the treatment developed by Cummings and Anderson with their collaborators, StemCells Inc., was the first of its kind in the world when it was announced in 2010.

In some ways, that made the family – and their team – a target.

Concerns about possible intruders prompted the couple to place a camera at their front door. Cummings’ tires have been slashed, he said, though he doesn’t know if that was the work of people who oppose the harvesting of human embryonic stem cells, animal-rights activists (angered by experiments on rodents) or perhaps a disgruntled student.

At the moment, Cummings and Anderson are running five research programs and leading 17 researchers. All of it is funded by $2.2 million in grants, much of it from California Institute for Regenerative Medicine, or CIRM.

Created by voter initiative – Proposition 71 in 2004 – CIRM is California’s $3 billion answer to federal restrictions on funding for stem-cell research. Those restrictions were started by the Bush administration and eased, but not eliminated, under President Obama.

Cummings said opposition to their research is based, in part, on incorrect assumptions.

A big one is that the research involves the destruction of embryos. In reality, they work with balls of cells created at an earlier stage of human development, called blastocysts – a distinction many opponents do not draw.

“Embryonic stem cells don’t come from embryos,” he said. “And they never have.”

The raw material comes from fertility clinics and otherwise would be discarded.

Cummings says those who say that such research is immoral have it wrong.

“The argument is backward,” he said. “It’s immoral to throw away this stuff and not use it to help someone.”

••

During their meeting with the Andermings, project leader Hal Nguyen described the group’s plan to grow a series of stem-cell cultures and check a compelling question: Is some of a stem cell’s transformation guided by the microscopic environment in which it dwells, or is it entirely dictated by the cell’s internal workings?

“The plan is in the email,” Nguyen told Anderson.

“Dude, I have 400 emails,” Anderson said.

The group’s task was meant to answer a classic nature-nurture question, Anderson said. In this case, “nature” is the DNA coding in the stem cell itself, while “nurture” is the cellular environment, with all its floating nutrients and chemical signals.

“Will that environment, the extrinsic factor, trump anything the cell can do?” Anderson had wondered earlier. “Or is the intrinsic programming of the cell the principal determinant? Is that the main driving factor?”

Cummings stood by in the tiny meeting room while the researchers batted around their questions and answers. He said Anderson, a spinal cord specialist, was the expert in this arena, though he couldn’t help piping in during a discussion of the medium in which the cells would be grown.

“You’re comparing two different medias, too?” Cummings asked.

“We all know what we’re talking about,” Anderson told him. “Don’t interrupt.”

Then it was on to a larger, mostly empty meeting room where Sheri Peterson, a doctoral candidate, wanted to test her presentation on Cummings and Anderson.

Her eventual target is an advancement committee that will determine her future. The presentation will be crucial in her quest for a Ph.D.

Peterson ran through an array of slides projected on a large screen to reveal her findings. Inflammation of damaged tissue being regenerated in rats, she said, might be eased or worsened simply by manipulating proteins surrounding the regenerating cells.

Again, the topic was in Anderson’s wheelhouse.

“My notes said, ‘Nicely done,’ ” Cummings told Peterson.

“He’s not an aficionado,” Anderson said.

The husband-and-wife researchers then provided her with a detailed, slide-by-slide critique.

•••

Cummings’ expertise centers on traumatic brain injury. But he also is an expert at the complex task of marshaling grant funding. On his office wall, a whiteboard densely covered with writing tells the story: Cummings must police incoming and outgoing grants like an air traffic controller, timing the grants and the work they fund to match years of employment for graduate students and staff members.

The grants come and go over months and years, and so do the students and staff. Get the timing wrong, and you might have funding with no researchers, or researchers with nothing to do.

“At UCI, I’m like a small-business owner,” Cummings said.

Over a hasty lunch in his office (cold sandwiches grabbed during a trip, with Anderson, to a nearby campus snack shop), Cummings spoke of the merging of home and office life.

Writing up grant requests takes up both researchers’ time. Often, as they write, Camryn is playing in the background, whether at home or at the office. And research collaborators can show up wanting to conduct interviews at any time, holidays included.

“I did draw a line in the sand at Christmas Eve,” Anderson said.

Cummings knows such stress has driven other husband-and-wife teams into open conflict. But that just isn’t his and Anderson’s style. In fact, he said, keeping a scientific perspective, even at home, might help keep things calm.

“There’s no need to be yelling and shouting at each other because we don’t think that way,” he said. “You’re supposed to believe nothing until you prove it.”

That doesn’t mean they don’t differ, sometimes strongly, over scientific details.

“They don’t always agree with each other, and that’s good,” said Brittany Greer, an intern in their lab and an Anderming.

Nurturing the students and young scientists is part of the pleasure of doing science for both halves of the research couple, Anderson said.

“You start to look at this crowd of people as your second family,” she said. “They’re your kids. That is fun and rewarding for sure.”

You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

See the original post:
Stem-cell scientists find right chemistry

Posted in Cell Medicine | Comments Off

Plethora of New Products to be Showcased at 2012 Molecular Medicine Tri-Conference

Posted: February 18, 2012 at 9:19 am

Needham, MA (PRWEB) February 17, 2012

Cambridge Healthtech Institute announces 47 exhibitors & sponsors to showcase new products at the 19th Molecular Medicine Tri-Conference, taking place February 19-23, at the Moscone North Convention Center, San Francisco, CA. The Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating the entire spectrum of drug development.

The Molecular Medicine Tri-Conference has experienced seven straight years of attendee growth, while maintaining a high quality audience. This year’s event is on track to be another successful event. Spanning three days, the meeting is built around 5 scientific channels, encompassing 13 conferences, providing attendees more learning opportunities than ever before.

The 2012 event includes the New Product Showcase, where 47 companies will showcase their new products to event delegates.

New Products Include:
Abnova
Captor™- Captor™ is a label-free microfiltration system for isolation, enumeration, and retrieval of circulating tumor cells (CTCs) for translational research, preclinical and clinical studies.

Collaborative Drug Discovery (CDD)
Collaborative Drug Discovery (CDD) Vault® for molecular registration and SAR is:
Lightweight for budget-sensitive labs
Collaborative to scale
Are you a curious scientist?
Explore CDD - Booth #316

ELSEVIER
Target Insights - Target Insights is an online decision support tool in the drug discovery space. It enables users to identify, prioritize and validate biological targets more quickly and with less risk.

Ingenuity® Systems
Ingenuity ® iReport ™ - Ingenuity ® iReport ™ is a highly visual, interactive report that rapidly translates a single expression dataset into actionable biological insights through combined statistical and biological analysis.

MetanomicsHealth
MxPTM-Energy- MetanomicsHealth combines state-of-the-art metabolite profiling, which enables the analysis of endogenous and xenobiotic metabolites produced during cellular metabolism, with innovative bioinformatics and data mining systems to gain insight into the mechanistic basis of diseases and determine responses to drugs, nutritional or toxic effects. MetanomicsHealth’s targeted energy platform is used to describe physiological conditions affecting the energy status of a cell as well as cell proliferation or apoptosis, processes of high relevance in the area of oncology.

REMEDY Informatics
InvestigateTM - The Translational Informatics System - InvestigateTM accelerates translational research with 360-degree integration of bench-to-bedside data types, intuitive visual analytics for pattern recognition, a collaborative and extensible ontology, and LIMS, ELN, biospecimen, and clinical registry management.
SurModics
SurModics® Assay Diluent (Protein-Free) & TMB Enhanced One Component HRP Membrane Substrate & StabilBlot™ Blocker Family
SurModics® Assay Diluent (Protein-Free) - SurModics assay diluent was developed to reduce matrix interference in samples including heterophilic antibodies, such as HAMA (human anti-mouse antibody) and RF (rheumatoid factor). Data indicate that it significantly increases to signal-to-noise ratios and provides a protein-free alternative.
TMB Enhanced One Component HRP Membrane Substrate – SurModics TMB Enhanced One Component HRP Membrane Substrate is a ready to use solution containing 3,3’, 5,5’-tetramethylbenzidine in a mildly acidic buffer. The substrate reacts with peroxidase to form an insoluble permanent dark blue/purple color on the membrane or surface to which it is applied. This enhanced formulation extends the dynamic range of detection, especially at higher concentrations of peroxidase where other substrates may exhibit loss of signal due to washout effects.
StabilBlot™ Blocker Family - The StabilBlot™ Blocker Family is formulated to minimize background and enhance sensitivity in blotting applications. Choose from four formulations to customize based on your assay requirements: Protein-Free, BSA, Casein, and Milk.
TECAN
HP D300 Digital Dispenser - Tecan introduces the HP D300 Digital Dispenser. This benchtop instrument dispenses picoliter to microliter sample volumes to create dose response curves. IC50 determinations can be shortened from hours or days to just minutes.

Abbott Molecular
Vysis ALK Break Apart FISH Probe Kit - The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin?fixed paraffin?embedded (FFPE) non?small cell lung cancer (NSCLC) tissue specimens to aid in identifying those patients eligible for treatment with Xalkori® (crizotinib). FDA Approved
c-Kit RUO Kit A Sequencing Assay - The c?Kit RUO* Kit A is a Research Use Only in vitro assay for determining the mutations in exons 11, 13, 17, and 18 of the human c?Kit gene. *Not for use in diagnostic procedures.

ABS Inc.
Advanced Mycoplasma Testing Service - ABS is providing a new testing service for the detection of Mycoplasma contamination in cell cultures that is a new Gold Standard for objective unambiguous results.

Advanced Cell Diagnostics
RNAscope 2.0 - RNAscope is a breakthrough RNA in situ hybridization (ISH) method that enables routine detection and in situ visualization of virtually any gene at single-molecule sensitivity in formalin-fixed paraffin-embedded (FFPE) tissue.

Ambry Genetics
CLIA EXOME – Ambry Genetics is the first to provide researchers with CLIA exome sequencing services. Our service can be used for biomarker discovery, tumor analysis, pharmacogenomics response and Mendelian disease gene discovery.
AXXIN
Axxin T16 - Isothermal Instrument - Axxin’s advanced isothermal instrument enables the next generation of diagnostic DNA/RNA amplification in a compact, low cost, and sensitive instrument suitable for point of care diagnostic applications. Configured for up to 16 tubes simultaneously and 3 fluorophores.
BioGenex
Xmatrix Infinity - Fully automated and flexible instrument capable of performing IHC, ISH, FISH, CISH, IF and co-detection and multiplexing of protein and nucleic acid biomarkers. Double Stain Detection System - BioGenex double staining detection system is a biotin-free, super sensitive system, which provides a robust detection for visualizing multiple antigens simultaneously on the same tissue sample. It can be used with mouse and rabbit antibodies. MicroRNA in situ detection kits - Using fluorescein labeled probe, BioGenex microRNA in situ detection kits yield exceptional sensitivity and specificity enabling visualization of miRNA in difficult FFPE samples by either chromogenic or fluorescent detection systems.

Bioneer
ExiStation™ Molecular Diagnostics system - ExiStation™ is able to process on average 36 samples/hour, is able to handle up to 6 different types of clinical samples within a single run and is a pipetting-free system.

BioScale, Inc.
ViBE Protein Analysis Workstation – AMMP Phospho-Protein Assay - BioScale’s ViBE Protein Analysis Workstation and AMMP assays significantly improve sensitivity, accelerate the time-to-results and reduce assay development time for phospho-protein analysis including pP38, pERK1/2, pJNK, pAKT, pALK, & MEK.
BioView USA, Inc.
Circulating Tumor Cell System - BioView’s newly developed Circulating Tumor Cell application provides automatic scanning for the detection, capture, enumeration and retrieval of cellular and marker characteristics of any type of enriched sample hybridized with any combination of fluorescent antibodies.
Complete Genomics
Complete Genomics Cancer Sequencing Service – The Cancer Sequencing Service provides whole human genome sequencing of cancer pairs or trios, delivering somatic and germline variations including SNP’s, indels, CNV’s, structural variations, and mobile element insertions.
Computype
Tube Pro Labeling System – Label Print – and – Apply System for a wide variety of tubes and vials, including eppendorf tubes. For more information, please visit us at Booth#220.
Covance
Covance Discovery and Translational Services - Covance Discovery and Translational Services provides broad capabilities and in-depth scientific and technical expertise to enable faster go/no go decisions. Our scientific teams have industry experience supporting drug discovery and development and work in facilities purpose built by pharmaceutical companies for drug development. Whether you need a single study or a comprehensive discovery and translational services program, Covance offers extensive resources and industry expertise to help you solve your toughest development challenges.
Crown Bioscience Inc.
HuPrime®2.0 - CrownBio’s proven commitment to building broader, deeper, smarter PDX models, HuPrime®2.0 is the next generation of world’s largest collection genetically characterized human patient tumorgraft invivo models. Check us out today!
Cyagen
Vector Builder- Vector Builder is a versatile online tool in which you can design your own experimental DNA vectors! Then save time and have us custom build them at a highly competitive price.
Cytel Inc
Adaptive Clinical Trials for Oncology – Cytel Inc is a leading provider of clinical trial services and specialized statistical software for biopharmaceutical, medical device, academic and government research. markets.
Fluxion Biosciences
IsoFlux™ Rare Cell Access System - The IsoFlux™ Rare Cell Access System provides a new direction for clinical research. It isolates rare cells from a wide range of clinical samples and makes them available for further analysis using the proprietary CellSpot™ Technology.
fortéBIO
ForteBio introduces BLItz, a personal system for micro-volume, label-free analysis - BLItz™ tests for protein presence, does protein quantitation and measures binding kinetics effortlessly in just a drop of sample. Cleverly priced under $20K. Drop. Read. Done. Genius! Try BLItz at Booth 500.

General Atomics, Nirvana Division
Nirvana Storage Resource Broker (SRB)- Nirvana SRB federates complex legacy environments, providing storage virtualization and metadata management solutions for high-value unstructured data. A unified operations view simplifies migrations, synchronizations, and data management tasks.

Jubilant Biosys Ltd.
HTS and Ion Channel Screening - Jubilant’s added expertise in Electrophysiology, High Throughput Screening and In Vitro Biology, enabling Ion channel target prosecution in addition to GPCR’s and Kinases leverages expertize across global discovery centers.

Linguamatics
I2E MANAGED SERVICES - I2E Managed Services is a cloud-based text mining service tailored for each customer’s needs for content and vocabularies from both internal and external sources.
Lonza
NodeSensor™ Assays – are made up of two interacting proteins co-expressed in a human cell line. They enable sensitive and high content detection and measurement, using inherently proteins as reporters.
Norgen Biotek
RNA Extraction Services- Norgen offers RNA Extraction services from all types of samples at a reasonable price. Have our specialists isolate RNA (including microRNA) from your samples, guaranteeing total RNA of the utmost quality and yield.

Oxford Gene Technology
NGS – Targeted Sequencing Services - Our comprehensive targeted sequencing service takes you all the way from project design to high-quality, filtered results. Unique and complimentary analysis software provides fast and intuitive access to prioritized results. For more information please contact: OGT Diagnostic Biomarkers, Begbroke Science Park, Sandy Lane, Yarnton, Oxford, OX51PF, T: 0044 (0) 1865 856826, F: 0044 (0) 1865 848684, E: products@ogt.co.uk

Omni International – The Homogenizer Company
Omni LH96 Automated Homogenizer Workstation - The Omni LH96: homogenize, dispense liquids, pipette, weigh, and eliminate cross-contamination - all with one space-saving automated device. What used to take hours can now be completed in minutes!
Optibrium Ltd
StarDrop - StarDrop is a suite of software for guiding decisions in drug discovery, helping project teams identify high-quality compounds, fast.
Parthys Reverse Informatics
Periodic Technology Alerts for Drug Targets - Our alert reports are empowered by synonyms dictionary, which enables us to supply the latest patent applications & patents on your drug target of interest at intervals determined by you!

Platform Computing, an IBM Company
Platform Symphony MapReduce - Platform Symphony MapReduce is a best-of-breed, enterprise-class distributed runtime engine for MapReduce applications. While 100% compatible with open source Hadoop, Platform Symphony MapReduce provides unique capabilities such as a mixed workload support, dynamic resource sharing and high availability of HDFS NameNode to ensure success deployment of Hadoop applications into production environment. With Platform Symphony MapReduce, organizations benefit from faster performance, high resource utilization (75% sustained level), improved reliability and manageability with their IT infrastructure.

Randox Laboratories
KRAS, BRAF and PIK3CA Biochip Arrays – Randox announces the launch of the world’s first Biochip Array capable of detecting 20 mutations across KRAS, BRAF and PIK3CA, utilizing a rapid, sensitive, single tube, multiplex PCR.

Rubicon Genomics
NovaPLEX Prep Kits - Rubicon has introduced its NovaPLEX™ Prep Kit family, including ThruPLEX™-FD and PicoPLEX™-SC NGS prep kits for fragmented DNA and single cells, as well as OmniPLEX™ preps for diagnostic microarrays.

SARmont LLC
Medicinal Chemistry Design and Lead Optimization Services – Design services led by Dr. John Talley, CSO, the inventor of Celebrex and seven other FDA approved drugs. Early stage design and lead optimization services – all IP is retained by the client. Cost efficient compound synthesis via our strategic CRO partner in India, Escientia.

Sequenom
iPLEX® ADME PGx panel - iPLEX® ADME PGx panel empowers your screening and validation of genotypes associated with drug metabolism. Simultaneously analyze 192 mutations in 36 pharmacogenetically relevant genes and identify SNPs, INDELS, and CNVs.

Silicon Biosystems, Inc.
Silicon Biosystems’ DEPArray™ Platform, utilizing image-based cell selection, is ideally suited to isolate single cells without contact, from enriched blood samples, such as CTCs and Stem Cells, with 100% purity.

SomaLogic
SOMAscan - SomaLogic’s unique SOMAscan™ technology protein biomarker discovery for target discovery and validation, clinical and companion diagnostic development, drug discovery and development, clinical trial design and execution, drug response, and understanding disease biology.

Sony DADC
SiMoA - Production of the SiMoA consumable is very similar to the manufacturing techniques used for DVD optical discs. Two injection molded discs with microstructures are bonded by laser welding to achieve a laminated final product.

Spry Inc.
Agile Analytics - Agile Analytics combines semantic technologies, agile development, and stakeholder engagement tactics to quickly develop data-rich gadgets capable of supporting interoperability analysis, policy compliance, data governance, investment analysis, and portfolio management.

The Jackson Laboratory
Diversity Outbred Mice (J:DO, Strain No. 009376) - The Diversity Outbred mouse is a new heterogeneous, highly diverse resource designed for complex trait analysis, toxicology/pharmacogenomic screens, compound evaluation studies, and to facilitate rapid mapping with single gene resolution.

TwistDx Limited
Release of TwistAmp™ exo RT - RT release date: 12th December - TwistDx are making available optimized reverse transcriptase (RT) kits to complement the current TwistAmp™ product line to permit a ‘one-step’ RNA amplification / detection reaction. For further information please contact: TwistDx Limited Minerva Building, Babraham Research Campus, Babraham, Cambridge UK CB22 3AT, T; +44 (0) 1223 496703, M; +44 (0) 7827 975 283, http://www.twistdx.co.uk

UNIConnect
UNIFlow-MDx - The UNIFlow MDx LIMS has been designed to capture all the complex processes of in a molecular lab – even processes that are changing and evolving with the science.

Veridex LLC
Using rare cell technology CellSearch, we have developed an automated assay for enriching, detecting and characterizing circulating multiple myeloma cells (CMMC) in the blood of patients diagnosed with Multiple Myeloma

View list and description of new products

About Molecular Medicine Tri-Conference
Molecular Medicine Tri-Conference -- the flagship event of CHI - has built this year's event around 5 scientific channels, encompassing 13 conferences, providing attendees more learning opportunities than ever before. Featured channels include diagnostics, chemistry, informatics, biologics, cancer and executive. We are looking to provide attendees a more in depth experience into each of these seven areas of research and development. As the need for better information, new technologies, improved strategies and competitive intelligence becomes ever more acute, this event provides compelling research insight into the future of molecular medicine. In 2012, we expect 3,000 attendees, 1,200 participating companies, 160 exhibitors, 120+ posters, and representatives from over 38 countries. http://www.TriConference.com

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. http://www.chicorporate.com

Contact:
Tracey Fielding
Cambridge Healthtech Institute
Ph. 781-972-5429
tfielding(at)healthtech(dot)com

# # #

Read the rest here:
Plethora of New Products to be Showcased at 2012 Molecular Medicine Tri-Conference

Posted in Molecular Medicine | Comments Off

Page 2,857«..10 20..2,8562,8572,858 2,859..2,870 2,880..»

privacy controlled social networking to connect patients with caregivers

SOCIAL CRM and its Impact on Pharmaceutical Industry

ACT's Top Scientist Sells $1.5 Million in Company Stock

CIRM Contracting: $1.3 Million for IT, $887,282 for Legal

Stem Cell Agency on Bee Article and Voter Expectations

Blue-Ribbon Panel Seeks Public Comment on California Stem Cell Agency

Edmond Veterinary Hospital Offers Pet Stem Cell Therapy for Arthritis

Stem cells used to increase bone strength

Stem-cell scientists find right chemistry

Plethora of New Products to be Showcased at 2012 Molecular Medicine Tri-Conference

Categories

Archives

Recommended Sites

Contact Us

Recent Posts